Suscribirse

Is serum gentamicin concentration modified with autologous cell-saved blood transfusion after total knee arthroplasty using tranexamic acid? A randomised control trial - 27/04/21

Doi : 10.1016/j.otsr.2020.102794 
Panagiotis Touzopoulos a, , Konstantinos Arvanitidis b, Eirini Filidou b, Konstantinos Tilkeridis c, Michael Karanikas d, George Kolios b, Athanasios Ververidis c
a Department of Orthopaedics, General University Hospital of Alexandroupolis, Alexandroupolis, Greece 
b Laboratory of Pharmacology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece 
c Department of Orthopaedics, Medical School, Democritus University of Thrace, Alexandroupolis, Greece 
d Department of Surgery, Medical School, Democritus University of Thrace, Alexandroupolis, Greece 

Corresponding author.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Abstract

Background

Self-transfusion has been proven as an effective management of blood loss after total knee arthroplasty (TKA). Considering that the high local concentration of antibiotic from bone cement is delivered intravenously through the self-transfusion process, systematic toxicity has never been evaluated. In addition, the effectiveness of self-transfusion with the routine concomitant use of other modern blood-salvage strategies, like tranexamic acid, should also be assessed. Therefore, we performed a randomised study to assess: 1) the safety of self-transfusion in TKA by comparing the gentamicin concentrations resulting from the use or not of autologous blood transfusion; 2) the efficacy of self-transfusion in TKA, with the concomitant administration of tranexamic acid.

Hypothesis

Self-transfusion in TKA elevates the serum gentamicin concentration and the potential risk of nephrotoxicity.

Methods

The serum concentration of aminoglycosides was measured in two groups of 20 patients each, after TKA, according to the use of self-transfusion. Hemoglobin, renal function and calculated blood loss were compared at several points in time between groups.

Results

The only time where there was a statistically significant difference in serum gentamicin, was at 48h postoperatively between groups [0.3 ug/mL±0.21, range: 0.15 to 0.72 vs. 0.14ug/mL±0.1, range: 0 to 0.35 (p=0.02)]. There were no significant differences in total blood loss [1341mL±501, range: 830 to 2230 vs. 1263mL±459 range: 840 to 2480 (p=0.67)] and need of allogeneic blood transfusion [3 units vs. 2 units] between groups.

Conclusion

The use of autologous blood transfusion was found to be safe, in terms of nephrotoxicity of aminoglycosides after TKA, but it seemed to be ineffective as a blood salvage strategy, when used concomitantly with the administration of tranexamic acid.

Level of evidence

II; low-powered randomised study.

ClinicalTrials.gov registration number

NCT04505748.

El texto completo de este artículo está disponible en PDF.

Keywords : Gentamicin, Self-transfusion, Blood loss, Toxicity, Total knee, Tranexamic acid


Esquema


© 2020  Elsevier Masson SAS. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 107 - N° 3

Artículo 102794- mai 2021 Regresar al número
Artículo precedente Artículo precedente
  • Blood loss after revision knee arthroplasty is 1.38- to 2.17-fold higher than after primary knee arthroplasty: A retrospective analysis of 898 cases
  • Antonio Klasan, Florian Gerber, Arne Schermuksnies, Sven Edward Putnis, Thomas Neri, Thomas Jan Heyse
| Artículo siguiente Artículo siguiente
  • Navigated total knee arthroplasty: Retrospective study of 600 continuous cases
  • Jean-Claude Bové, Arnaud Clavé

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.